2023 Clinic Diagnostic Imaging Nuclear Medicine 
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We This oversight has led to program launch setbacks, Beyder explained.
Imaging Technology
JUNE 25, 2023
The new slate of officers was introduced during the Society of Nuclear Medicine and Molecular Imaging’s 2023 Annual Meeting, held June 24-27. “I I and am very passionate about supporting the nuclear medicine technologist profession through advocacy and volunteerism.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. This drug relies on a gallium Ga-68, too, as a diagnostic imaging agent.
Imaging Technology
JULY 3, 2023
milla1cf Mon, 07/03/2023 - 20:06 July 3, 2023 — RefleXion Medical , Inc., milla1cf Mon, 07/03/2023 - 20:06 July 3, 2023 — RefleXion Medical , Inc., For more information: www.reflexion.com Monday, July 3, 2023 - 20:07 City of Hope, one of the largest cancer research and treatment organizations in the U.S.,
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. This drug relies on a gallium Ga-68, too, as a diagnostic imaging agent.
Expert insights. Personalized for you.
105 
Let's personalize your content